Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor AG3340 [prinomastat] in Combination With Mitoxantrone and Prednisone With Provision for Subsequent Change in Therapy in Patients Having Hormone-Refractory Prostate Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Prinomastat (Primary) ; Mitoxantrone; Prednisone
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- 22 Sep 2009 Actual end date (1 Jan 2001) added as reported by ClinicalTrials.gov
- 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 29 Sep 2005 New trial record.